Endocan: A Novel Marker for Colchicine Resistance in Familial Mediterranean Fever Patients?

Introduction: Familial Mediterranean fever (FMF) patients had 5–10% colchicine resistance. Although FMF attacks are characterized by acute phase elevation, there are no biomarkers that can show colchicine resistance yet. The serum endocan levels may elevate in inflammatory and auto-inflammatory diseases. Objectives: This study aimed to evaluate serum endocan levels in FMF patients according to whether attack and colchicine resistance or not and also compare them with classical acute phase reactants. Methods: In this single-center and cross-sectional study, a total of 111 FMF patients and 60 healthy individuals were enrolled. All patients' basic demographic and clinical data were recorded and blood samples were collected. Results: A total of 46 (41.4%) FMF patients had colchicine resistance. In comparison to the FMF patients according to colchicine response, colchicine resistance patients had a significantly higher median (IQR) endocan levels than colchicine responsive patients [36.98 ng/ml (97.41) vs. 13.57 ng/ml (27.87), p = 0.007], but there were no differences between in terms of median ESR and CRP levels. Inversely, serum endocan levels were similar during an attack and attack-free period in FMF patients, although ESR and CRP levels were significantly different. Interestingly, the highest serum endocan levels were in the control group. Conclusion: In conclusion, serum endocan levels were higher in colchicine resistance than colchicine responsive patients, but attack state had no effect on serum endocan levels in our study. Unlike ESR and CRP, serum endocan may be a novel biomarker for detection of colchicine resistance and distinguish the FMF attacks.

[1]  O. Küçükşahin,et al.  Different pharmaceutical preparations of colchicine for Familial Mediterranean Fever: are they the same? , 2019, Rheumatology International.

[2]  I. Kupeli,et al.  Can endocan be a new biomarker in ventilator‐associated pneumonia? , 2018, The Kaohsiung journal of medical sciences.

[3]  S. Özen,et al.  Which definition should be used to determine colchicine resistance among patients with familial Mediterranean fever? , 2018, Clinical and experimental rheumatology.

[4]  A. Erden,et al.  Blood group 'A' may have a possible modifier effect on familial Mediterranean fever and blood group '0' may be associated with colchicine resistance. , 2018, Biomarkers in medicine.

[5]  M. Karamanou,et al.  Isolating Colchicine in 19th Century: An Old Drug Revisited. , 2018, Current pharmaceutical design.

[6]  M. Yildizgoren,et al.  Anti-interleukin-1 treatment in 26 patients with refractory familial mediterranean fever , 2017, Modern rheumatology.

[7]  T. Voiosu,et al.  Endocan, Novel Potential Biomarker for Systemic Sclerosis: Results of a Pilot Study , 2016, Journal of clinical laboratory analysis.

[8]  M. Yılmaz,et al.  Relationship between endothelial dysfunction and microalbuminuria in familial Mediterranean fever. , 2016, European journal of rheumatology.

[9]  S. Ozen,et al.  What is the best acute phase reactant for familial Mediterranean fever follow-up and its role in the prediction of complications? A systematic review , 2016, Rheumatology International.

[10]  I. Ozer,et al.  Association between colchicine resistance and vitamin D in familial Mediterranean fever , 2015, Renal failure.

[11]  S. Ozen,et al.  The myths we believed in familial Mediterranean fever: what have we learned in the past years? , 2015, Seminars in Immunopathology.

[12]  G. Grassi,et al.  Endocan, a novel marker of endothelial dysfunction in patients with essential hypertension: Comparative effects of amlodipine and valsartan , 2015, Blood pressure.

[13]  J. Carrero,et al.  Endothelial function in patients with familial Mediterranean fever-related amyloidosis and association with cardiovascular events. , 2014, Rheumatology.

[14]  A. Gül.  Treatment of familial Mediterranean fever: colchicine and beyond. , 2014, The Israel Medical Association journal : IMAJ.

[15]  T. Celik,et al.  Aortic Arterial Stiffness is a Moderate Predictor of Cardiovascular Disease in Patients With Psoriasis Vulgaris , 2014, Angiology.

[16]  Shun-Fa Yang,et al.  Plasma endothelial cell-specific molecule-1 (ESM-1) in management of community-acquired pneumonia , 2013, Clinical chemistry and laboratory medicine.

[17]  D. Mikhailidis,et al.  Elevated serum levels of endocan in patients with psoriasis vulgaris: correlations with cardiovascular risk and activity of disease , 2013, The British journal of dermatology.

[18]  Ricardo Araya,et al.  Results: pilot study , 2013 .

[19]  W. Wei,et al.  Expression and distribution of endocan in human tissues , 2012, Biotechnic & histochemistry : official publication of the Biological Stain Commission.

[20]  D. Mikhailidis,et al.  Lipid lowering agents and the endothelium: an update after 4 years. , 2012, Current vascular pharmacology.

[21]  I. Ben-Zvi,et al.  Chronic inflammation in FMF: markers, risk factors, outcomes and therapy , 2011, Nature Reviews Rheumatology.

[22]  E. Hasanoǧlu,et al.  Unresponsiveness to Colchicine Therapy in Patients with Familial Mediterranean Fever Homozygous for the M694V Mutation , 2010, The Journal of Rheumatology.

[23]  B. Reichman,et al.  A single testing of serum amyloid a levels as a tool for diagnosis and treatment dilemmas in familial Mediterranean fever. , 2007, Seminars in arthritis and rheumatism.

[24]  U. Yasar,et al.  Association of drug transporter gene ABCB1 (MDR1) 3435C to T polymorphism with colchicine response in familial Mediterranean fever. , 2007, The Journal of rheumatology.

[25]  D. Booth,et al.  Clinical and subclinical inflammation in patients with familial Mediterranean fever and in heterozygous carriers of MEFV mutations. , 2006, Rheumatology.

[26]  M. Chiariello,et al.  Cellular adhesion molecules and peripheral arterial disease , 2006, Vascular medicine.

[27]  M. Lyon,et al.  Endocan or endothelial cell specific molecule-1 (ESM-1): a potential novel endothelial cell marker and a new target for cancer therapy. , 2006, Biochimica et biophysica acta.

[28]  M. Pras,et al.  Severe disease in patients with rheumatoid arthritis carrying a mutation in the Mediterranean fever gene , 2005, Annals of the rheumatic diseases.

[29]  R. Gershoni-baruch,et al.  Colchicine nonresponsiveness in familial Mediterranean fever: clinical, genetic, pharmacokinetic, and socioeconomic characterization. , 2004, Seminars in arthritis and rheumatism.

[30]  A. Bakkaloğlu,et al.  Role of A-SAA in monitoring subclinical inflammation and in colchicine dosage in familial Mediterranean fever. , 2003, Clinical and experimental rheumatology.

[31]  H. Yazici,et al.  Acute phase response in familial Mediterranean fever , 2002, Annals of the rheumatic diseases.

[32]  H. Hammad,et al.  Human Endothelial-Cell Specific Molecule-1 Binds Directly to the Integrin CD11a/CD18 (LFA-1) and Blocks Binding to Intercellular Adhesion Molecule-11 , 2001, The Journal of Immunology.

[33]  D. Zemer,et al.  Criteria for the diagnosis of familial Mediterranean fever. , 1997, Arthritis and rheumatism.

[34]  D. Zemer,et al.  Colchicine in the treatment of AA and AL amyloidosis. , 1993, Seminars in arthritis and rheumatism.